Oppenheimer analyst Hartaj Singh raised the firm’s price target on Vertex Pharmaceuticals to $450 from $430 and keeps an Outperform rating on the shares ahead of the earnings report on February 5. With multiple and material catalysts in 2024 in acute pain, CF and kidney disease in 2024, Vertex stock should work, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX: